All Stories

  1. Transfection of the BDNF Gene in the Surviving Dopamine Neurons in Conjunction with Continuous Administration of Pramipexole Restores Normal Motor Behavior in a Bilateral Rat Model of Parkinson’s Disease
  2. Modulation of D3R Splicing, Signaling, and Expression by D1R through PKA→PTB Phosphorylation
  3. Dopamine D3 receptor modulates D2 receptor effects on cAMP and GABA release at striatopallidal terminals—Modulation by the Ca2+–Calmodulin–CaMKII system
  4. PEG 400:Trehalose Coating Enhances Curcumin-Loaded PLGA Nanoparticle Internalization in Neuronal Cells
  5. Pharmacological targeting of G protein-coupled receptor heteromers
  6. Repositioning of drugs for Parkinson’s disease and pharmaceutical nanotechnology tools for their optimization
  7. Hypothalamic A11 Nuclei Regulate the Circadian Rhythm of Spinal Mechanonociception through Dopamine Receptors and Clock Gene Expression
  8. Presynaptic nigral GPR55 receptors stimulate [ 3 H]‐GABA release through [ 3 H]‐cAMP production and PKA activation and promote motor behavior
  9. Optoception: Perception of Optogenetic Brain Perturbations
  10. Association of α-1-Antichymotrypsin Expression with the Development of Conformational Changes of Tau Protein in Alzheimer’s Disease Brain
  11. Day-Night Variations in the Concentration of Neurotransmitters in the Rat Lumbar Spinal Cord
  12. Current progress of self-healing polymers for medical applications in tissue engineering
  13. Optoception: perception of optogenetic brain stimulation
  14. Molecular Processing of Tau Protein in Progressive Supranuclear Palsy: Neuronal and Glial Degeneration
  15. Curcumin for parkinson´s disease: potential therapeutic effects, molecular mechanisms, and nanoformulations to enhance its efficacy
  16. CB1/5-HT/GABA interactions and food intake regulation
  17. Dopamine D4 receptor modulates inhibitory transmission in pallido‐pallidal terminals and regulates motor behavior
  18. Activation of STAT3 Regulates Reactive Astrogliosis and Neuronal Death Induced by AβO Neurotoxicity
  19. Chitosan-decorated nanoparticles for drug delivery
  20. Early but not late conformational changes of tau in association with ubiquitination of neurofibrillary pathology in Alzheimer’s disease brains
  21. Hypothalamic A11 Nuclei Regulate the Circadian Rhythm of the Mechanonociception and the Spinal Clock Gene Transcription through Dopamine Receptor Activation
  22. The treatment of Goji berry (Lycium barbarum) improves the neuroplasticity of the prefrontal cortex and hippocampus in aged rats
  23. γ-Aminobutyric acid (GABA) from satellite glial cells tonically depresses the excitability of primary afferent fibers
  24. A Reevaluation of Chitosan-Decorated Nanoparticles to Cross the Blood-Brain Barrier
  25. RECENT ADVANCES IN ELASTIN-BASED BIOMATERIALS
  26. Xanthan gum in drug release
  27. Hyaluronic acid in wound dressings
  28. Coexistence of D 3 R typical and atypical signaling in striatonigral neurons during dopaminergic denervation. Correlation with D 3 nf expression changes
  29. Differential calcium channel‐mediated dopaminergic modulation in the subthalamonigral synapse
  30. Cannabinoids CB2 Receptors, One New Promising Drug Target for Chronic and Degenerative Pain Conditions in Equine Veterinary Patients
  31. Cdk5 phosphorylates CaV1.3 channels and regulates GABAA-mediated miniature inhibitory post-synaptic currents in striato-nigral terminals
  32. D 2 autoreceptor switches CB 2 receptor effects on [ 3 H]‐dopamine release in the striatum
  33. Blockade of Intranigral and Systemic D3 Receptors Stimulates Motor Activity in the Rat Promoting a Reciprocal Interaction Among Glutamate, Dopamine, and GABA
  34. Phospho-Tau Protein Expression in the Cell Cycle of SH-SY5Y Neuroblastoma Cells: A Morphological Study
  35. Severity of Dyskinesia and D3R Signaling Changes Induced by L-DOPA Treatment of Hemiparkinsonian Rats Are Features Inherent to the Treated Subjects
  36. Development and Evaluation of Alginate Membranes with Curcumin-Loaded Nanoparticles for Potential Wound-Healing Applications
  37. Presynaptic Control of [3H]-Glutamate Release by Dopamine Receptor Subtypes in the Rat Substantia Nigra. Central Role of D1 and D3 Receptors
  38. Formulations of Curcumin Nanoparticles for Brain Diseases
  39. CB1 receptors in the paraventricular nucleus of the hypothalamus modulate the release of 5-HT and GABA to stimulate food intake in rats
  40. Presynaptic cannabinoid CB2 receptors modulate [3 H]-Glutamate release at subthalamo-nigral terminals of the rat
  41. The neuropeptide-12 improves recognition memory and neuronal plasticity of the limbic system in old rats
  42. Presynaptic Dopamine D2 Receptors Modulate [ 3 H]GABA Release at StriatoPallidal Terminals via Activation of PLC → IP3 → Calcineurin and Inhibition of AC → cAMP → PKA Signaling Cascades
  43. Nanotechnology As Potential Tool for siRNA Delivery in Parkinson's Disease
  44. Curcuma treatment prevents cognitive deficit and alteration of neuronal morphology in the limbic system of aging rats
  45. Cannabinoid-induced depression of synaptic transmission is switched to stimulation when dopaminergic tone is increased in the globus pallidus of the rodent
  46. Fibrillar Amyloid-β Accumulation Triggers an Inflammatory Mechanism Leading to Hyperphosphorylation of the Carboxyl-Terminal End of Tau Polypeptide in the Hippocampal Formation of the 3×Tg-AD Transgenic Mouse
  47. Chronic administration of resveratrol prevents morphological changes in prefrontal cortex and hippocampus of aged rats
  48. Nanoparticle technology for treatment of Parkinson's disease: the role of surface phenomena in reaching the brain
  49. Neuroinflammation and Alteration of the Blood-Brain Barrier in Alzheimer´s Disease
  50. The relationship between truncation and phosphorylation at the C-terminus of tau protein in the paired helical filaments of Alzheimer's disease
  51. Dopaminergic denervation switches dopamine D3 receptor signaling and disrupts its Ca2+ dependent modulation by CaMKII and calmodulin in striatonigral projections of the rat
  52. Dopamine Receptors and Neurodegeneration
  53. Cannabinoid CB1 receptors activation and coactivation with D2 receptors modulate GABAergic neurotransmission in the globus pallidus and increase motor asymmetry
  54. Stimulation of dopamine D4 receptors in the paraventricular nucleus of the hypothalamus of male rats induces hyperphagia: Involvement of glutamate
  55. Accumulation of Abnormally Processed Tau Protein in Neuronal Cells as a Biomarker for Dementia
  56. Pathophysiology of L-Dopa Induced Dyskinesia — Changes in D1/D3 Receptors and Their Signaling Pathway
  57. L-type Ca2+ channel activity determines modulation of GABA release by dopamine in the substantia nigra reticulata and the globus pallidus of the rat
  58. Presynaptic CaMKIIα modulates dopamine D3 receptor activation in striatonigral terminals of the rat brain in a Ca2+ dependent manner
  59. D3 dopamine receptors interact with dopamine D1 but not D4 receptors in the GABAergic terminals of the SNr of the rat
  60. Phosphorylation of Tau Protein Associated as a Protective Mechanism in the Presence of Toxic, C-Terminally Truncated Tau in Alzheimer's Disease
  61. Changes on D2-like receptor induced Gi protein activation and hippocampal dopamine release in kindled rats
  62. Endogenous Content and Release of [3H]-GABA and [3H]-Glutamate in the Spinal Cord of Chronically Undernourished Rat
  63. Dopamine D4 receptor stimulation in GABAergic projections of the globus pallidus to the reticular thalamic nucleus and the substantia nigra reticulata of the rat decreases locomotor activity
  64. Dopamine D4 receptor, but not the ADHD-associated D4.7 variant, forms functional heteromers with the dopamine D2S receptor in the brain
  65. l-DOPA-induced dyskinesia in hemiparkinsonian rats is associated with up-regulation of adenylyl cyclase type V/VI and increased GABA release in the substantia nigra reticulata
  66. GABAB receptors modulate depolarization-stimulated [3H]glutamate release in slices of the pars reticulata of the rat substantia nigra
  67. Dopamine inhibits GABA transmission from the globus pallidus to the thalamic reticular nucleus via presynaptic D4 receptors
  68. Los Receptores Dopaminérgicos D2/D3 hipotalámicos particpan en la regulación del comportamiento alimentario
  69. D4 and D1 dopamine receptors modulate [3H]GABA release in the substantia nigra pars reticulata of the rat
  70. Role of cannabinoid CB1 receptors on macronutrient selection and satiety in rats
  71. Cannabinoid Agonists Stimulate [3H]GABA Release in the Globus Pallidus of the Rat When Gi Protein-Receptor Coupling Is Restricted: Role of Dopamine D2 Receptors
  72. 6-OHDA-induced hemiparkinsonism and chronic l-DOPA treatment increase dopamine D1-stimulated [3H]-GABA release and [3H]-cAMP production in substantia nigra pars reticulata of the rat
  73. Presynaptic D1 dopamine receptors facilitate glutamatergic neurotransmission in the rat globus pallidus
  74. GABAB receptor activation inhibits dopamine D1 receptor-mediated facilitation of [3H]GABA release in substantia nigra pars reticulata
  75. Dopamine D1 receptor facilitation of depolarization-induced release of γ-amino-butyric acid in rat striatum is mediated by the cAMP/PKA pathway and involves P/Q-type calcium channels
  76. Adenosine A2A receptor stimulation decreases GAT-1-mediated GABA uptake in the globus pallidus of the rat
  77. L-DOPA inhibits depolarization-induced [3H]GABA release in the dopamine-denervated globus pallidus of the rat: the effect is dopamine independent and mediated by D2-like receptors
  78. Control of the Subthalamic Innervation of Substantia Nigra Pars Reticulata by D1 and D2 Dopamine Receptors
  79. Activación de receptores dopaminérgicos por L-DOPA. De la acción terapéutica a las discinesias.
  80. Interactions between adenosine A2a and dopamine D2 receptors in the control of [3H]GABA release in the globus pallidus of the rat
  81. Dopamine D4 receptors inhibit depolarization-induced [3H]GABA release in the rat subthalamic nucleus
  82. Activation of dopamine D4 receptors modulates [3H]GABA release in slices of the rat thalamic reticular nucleus
  83. Adenosine A1 receptors control dopamine D1-dependent [3H]GABA release in slices of substantia nigra pars reticulata and motor behavior in the rat
  84. Intrapallidal dopamine restores motor deficits induced by 6-hydroxydopamine in the rat
  85. Histamine H3receptor-mediated inhibition of depolarization-induced, dopamine D1receptor-dependent release of [3H]-γ-aminobutyric acid from rat striatal slices
  86. Regulated release of serotonin from axonal growth cones isolated from the fetal rat brain
  87. D2 receptor-mediated inhibition of GABA release by endogenous dopamine in the rat globus pallidus
  88. Reciprocal interaction between glutamate and dopamine in the pars reticulata of the rat substantia nigra: a microdialysis study
  89. Histamine H3 receptor activation selectively inhibits dopamine D1 receptor-dependent [3H]GABA release from depolarization-stimulated slices of rat substantia nigra pars reticulata
  90. D-1 receptor mediated modulation of the release of γ-aminobutyric acid by endogenous dopamine in the basal ganglia of the rat
  91. D1 Receptor Mediated Trophic Action of Dopamine on the Synthesis of GABA at the Terminals of Striatal Projections
  92. Activation of D1 receptors stimulates accumulation of γ-aminobutyric acid in slices of the pars reticulata of 6-hydroxydopamine-lesioned rats
  93. l-DOPA stimulates the release of [3H]γ-aminobutyric acid in the basal ganglia of 6-hydroxydopamine lesioned rats
  94. Activation of D1 dopamine receptors stimulates the release of GABA in the basal ganglia of the rat
  95. Presynaptic modulation of the release of GABA by GABAA receptors in pars compacta and by GABAB receptors in pars reticulata of the rat substantia nigra